Novartis and Pear Therapeutics are joining forces to develop novel prescription digital therapeutics to treat patients with schizophrenia and multiple sclerosis (MS).
Digital therapeutics are software applications designed to treat diseases and improve clinical outcomes for patients. Combining Novartis’ expertise in biomedical research and clinical development with Pear’s knowledge in digital therapeutics will allow the companies to create these innovative treatment tools.
Pear Therapeutics is a leader in the development of prescription digital therapeutics, including patient-facing applications, clinical assessment and outcomes tracking, clinician monitoring dashboards, and insurance-related data storage. Its goal is to combine clinically relevant data and approved treatment regimens, including medications or medical devices, to improve patients’ lives.
Pear has a pipeline of different products, including Thrive, the first prescription digital therapeutic developed to treat schizophrenia. It consists of a patient-facing smartphone application and clinician-facing web interface to deliver 24/7, real-time monitoring and support to patients.
More information about the companies involved:
and
Novartis is the developer and seller of the schizophrenia medication called Fanapt.
Full story here:
and